These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
543 related articles for article (PubMed ID: 26996927)
1. The novel anti-CD19 chimeric antigen receptors with humanized scFv (single-chain variable fragment) trigger leukemia cell killing. Qian L; Li D; Ma L; He T; Qi F; Shen J; Lu XA Cell Immunol; 2016; 304-305():49-54. PubMed ID: 26996927 [TBL] [Abstract][Full Text] [Related]
2. Function of Novel Anti-CD19 Chimeric Antigen Receptors with Human Variable Regions Is Affected by Hinge and Transmembrane Domains. Alabanza L; Pegues M; Geldres C; Shi V; Wiltzius JJW; Sievers SA; Yang S; Kochenderfer JN Mol Ther; 2017 Nov; 25(11):2452-2465. PubMed ID: 28807568 [TBL] [Abstract][Full Text] [Related]
3. Construction of a new anti-CD19 chimeric antigen receptor and the anti-leukemia function study of the transduced T cells. An N; Tao Z; Li S; Xing H; Tang K; Tian Z; Rao Q; Wang M; Wang J Oncotarget; 2016 Mar; 7(9):10638-49. PubMed ID: 26840021 [TBL] [Abstract][Full Text] [Related]
4. A tandem CD19/CD20 CAR lentiviral vector drives on-target and off-target antigen modulation in leukemia cell lines. Schneider D; Xiong Y; Wu D; Nӧlle V; Schmitz S; Haso W; Kaiser A; Dropulic B; Orentas RJ J Immunother Cancer; 2017; 5():42. PubMed ID: 28515942 [TBL] [Abstract][Full Text] [Related]
5. Fully human CD19-specific chimeric antigen receptors for T-cell therapy. Sommermeyer D; Hill T; Shamah SM; Salter AI; Chen Y; Mohler KM; Riddell SR Leukemia; 2017 Oct; 31(10):2191-2199. PubMed ID: 28202953 [TBL] [Abstract][Full Text] [Related]
6. Adnectin-Based Design of Chimeric Antigen Receptor for T Cell Engineering. Han X; Cinay GE; Zhao Y; Guo Y; Zhang X; Wang P Mol Ther; 2017 Nov; 25(11):2466-2476. PubMed ID: 28784559 [TBL] [Abstract][Full Text] [Related]
7. Identification of Potent CD19 scFv for CAR T Cells through scFv Screening with NK/T-Cell Line. Kang CH; Kim Y; Lee HK; Lee SM; Jeong HG; Choi SU; Park CH Int J Mol Sci; 2020 Dec; 21(23):. PubMed ID: 33271901 [TBL] [Abstract][Full Text] [Related]
9. Genetically targeted T cells eradicate systemic acute lymphoblastic leukemia xenografts. Brentjens RJ; Santos E; Nikhamin Y; Yeh R; Matsushita M; La Perle K; Quintás-Cardama A; Larson SM; Sadelain M Clin Cancer Res; 2007 Sep; 13(18 Pt 1):5426-35. PubMed ID: 17855649 [TBL] [Abstract][Full Text] [Related]
10. Lenalidomide enhances the function of chimeric antigen receptor T cells against the epidermal growth factor receptor variant III by enhancing immune synapses. Kuramitsu S; Ohno M; Ohka F; Shiina S; Yamamichi A; Kato A; Tanahashi K; Motomura K; Kondo G; Kurimoto M; Senga T; Wakabayashi T; Natsume A Cancer Gene Ther; 2015 Oct; 22(10):487-95. PubMed ID: 26450624 [TBL] [Abstract][Full Text] [Related]
11. TGF-β/IL-7 Chimeric Switch Receptor-Expressing CAR-T Cells Inhibit Recurrence of CD19-Positive B Cell Lymphoma. Noh KE; Lee JH; Choi SY; Jung NC; Nam JH; Oh JS; Song JY; Seo HG; Wang Y; Lee HS; Lim DS Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445415 [TBL] [Abstract][Full Text] [Related]
12. CD28 costimulation provided through a CD19-specific chimeric antigen receptor enhances in vivo persistence and antitumor efficacy of adoptively transferred T cells. Kowolik CM; Topp MS; Gonzalez S; Pfeiffer T; Olivares S; Gonzalez N; Smith DD; Forman SJ; Jensen MC; Cooper LJ Cancer Res; 2006 Nov; 66(22):10995-1004. PubMed ID: 17108138 [TBL] [Abstract][Full Text] [Related]
13. Phase 1 clinical trial demonstrated that MUC1 positive metastatic seminal vesicle cancer can be effectively eradicated by modified Anti-MUC1 chimeric antigen receptor transduced T cells. You F; Jiang L; Zhang B; Lu Q; Zhou Q; Liao X; Wu H; Du K; Zhu Y; Meng H; Gong Z; Zong Y; Huang L; Lu M; Tang J; Li Y; Zhai X; Wang X; Ye S; Chen D; Yuan L; Qi L; Yang L Sci China Life Sci; 2016 Apr; 59(4):386-97. PubMed ID: 26961900 [TBL] [Abstract][Full Text] [Related]
14. Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo. Milone MC; Fish JD; Carpenito C; Carroll RG; Binder GK; Teachey D; Samanta M; Lakhal M; Gloss B; Danet-Desnoyers G; Campana D; Riley JL; Grupp SA; June CH Mol Ther; 2009 Aug; 17(8):1453-64. PubMed ID: 19384291 [TBL] [Abstract][Full Text] [Related]
15. Inclusion of an IgG1-Fc spacer abrogates efficacy of CD19 CAR T cells in a xenograft mouse model. Almåsbak H; Walseng E; Kristian A; Myhre MR; Suso EM; Munthe LA; Andersen JT; Wang MY; Kvalheim G; Gaudernack G; Kyte JA Gene Ther; 2015 May; 22(5):391-403. PubMed ID: 25652098 [TBL] [Abstract][Full Text] [Related]
16. Switch-mediated activation and retargeting of CAR-T cells for B-cell malignancies. Rodgers DT; Mazagova M; Hampton EN; Cao Y; Ramadoss NS; Hardy IR; Schulman A; Du J; Wang F; Singer O; Ma J; Nunez V; Shen J; Woods AK; Wright TM; Schultz PG; Kim CH; Young TS Proc Natl Acad Sci U S A; 2016 Jan; 113(4):E459-68. PubMed ID: 26759369 [TBL] [Abstract][Full Text] [Related]
18. Incorporation of a hinge domain improves the expansion of chimeric antigen receptor T cells. Qin L; Lai Y; Zhao R; Wei X; Weng J; Lai P; Li B; Lin S; Wang S; Wu Q; Liang Q; Li Y; Zhang X; Wu Y; Liu P; Yao Y; Pei D; Du X; Li P J Hematol Oncol; 2017 Mar; 10(1):68. PubMed ID: 28288656 [TBL] [Abstract][Full Text] [Related]
19. Modeling anti-CD19 CAR T cell therapy in humanized mice with human immunity and autologous leukemia. Jin CH; Xia J; Rafiq S; Huang X; Hu Z; Zhou X; Brentjens RJ; Yang YG EBioMedicine; 2019 Jan; 39():173-181. PubMed ID: 30579863 [TBL] [Abstract][Full Text] [Related]
20. T Cells Expressing CD19/CD20 Bispecific Chimeric Antigen Receptors Prevent Antigen Escape by Malignant B Cells. Zah E; Lin MY; Silva-Benedict A; Jensen MC; Chen YY Cancer Immunol Res; 2016 Jun; 4(6):498-508. PubMed ID: 27059623 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]